Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

212.72 -0.49 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,304,127
Open 213.60
Bid (Size) 206.50 (1)
Ask (Size) 216.00 (1)
Prev. Close 213.21
Today's Range 212.44 - 213.97
52wk Range 116.08 - 217.51
Shares Outstanding 181,934,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire

Performance

YTD
+65.28%
+65.28%
1 Month
-0.96%
-0.96%
3 Month
+2.67%
+2.67%
6 Month
+8.98%
+8.98%
1 Year
+73.78%
+73.78%

More News

Read More
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Via InvestorPlace
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,600 Today
Via Benzinga
The 7 Most Undervalued Sleeper Stocks to Buy Now: November 2023
Via InvestorPlace
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years
Via Benzinga
This High-Yield Dividend Stock Is a Proven Wealth Creator
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside.
Via Investor's Business Daily
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play'
Via Benzinga
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue
Via InvestorPlace
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
Looking At Seagen's Recent Unusual Options Activity
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
From Seagen Inc.
Via Business Wire
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
From Seagen Inc.
Via Business Wire
The 7 Most Undervalued Long-Term Stocks to Buy: October 2023
Via InvestorPlace
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Scheduled For November 1, 2023
Via Benzinga
Earnings Outlook For Seagen
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
Via Investor's Business Daily
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.